These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 8972024)

  • 21. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile.
    Greninger DA; Saint-Remy JM; Jacquemin M; Benhida A; DiMichele DM
    Haemophilia; 2008 Mar; 14(2):295-302. PubMed ID: 18081826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of plasma antibody epitopes and gene abnormalities in Japanese hemophilia A patients with factor VIII inhibitor.
    Sugihara T; Takahashi I; Kojima T; Okamoto Y; Yamamoto K; Kamiya T; Matsushita T; Saito H
    Nagoya J Med Sci; 2000 May; 63(1-2):25-39. PubMed ID: 10911718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epitope localization of anti-factor VIII monoclonal antibodies determined by recombinant peptides.
    Ware J; Toomey JR; Stafford DW
    Thromb Haemost; 1989 Apr; 61(2):225-9. PubMed ID: 2473538
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibitors in German hemophilia A patients treated with a double virus inactivated factor VIII concentrate bind to the C2 domain of FVIII light chain.
    Laub R; Di Giambattista M; Fondu P; Brackmann HH; Lenk H; Saenko EL; Felch M; Scandella D
    Thromb Haemost; 1999 Jan; 81(1):39-44. PubMed ID: 9974372
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epitope mapping of factor VIII inhibitor antibodies of Chinese origin.
    Huang CC; Shen MC; Chen JY; Hung MH; Hsu TC; Lin SW
    Br J Haematol; 2001 Jun; 113(4):915-24. PubMed ID: 11442484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains.
    Rawle FE; Shi CX; Brown B; McKinven A; Tinlin S; Graham FL; Hough C; Lillicrap D
    J Gene Med; 2004 Dec; 6(12):1358-68. PubMed ID: 15493040
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transgenic pigs produce functional human factor VIII in milk.
    Paleyanda RK; Velander WH; Lee TK; Scandella DH; Gwazdauskas FC; Knight JW; Hoyer LW; Drohan WN; Lubon H
    Nat Biotechnol; 1997 Oct; 15(10):971-5. PubMed ID: 9335047
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of human hybridoma clones isolated from hemophilia patients with specificity for different domains of coagulating factor VIII.
    Gharagozlou S; Ghods R; Bahrami ZS; Roohi A; Jeddi-Tehrani M; Conti-Fine BM; Sharifian RA; Rabbani H; Shokri F
    Hum Antibodies; 2003; 12(3):67-76. PubMed ID: 14646035
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of the B domain in proteolytic inactivation of activated coagulation factor VIII by activated protein C and activated factor X.
    Khrenov AV; Ananyeva NM; Saenko EL
    Blood Coagul Fibrinolysis; 2006 Jul; 17(5):379-88. PubMed ID: 16788314
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human factor VIII inhibitor alloantibodies with a C2 epitope inhibit factor Xa-catalyzed factor VIII activation: a new anti-factor VIII inhibitory mechanism.
    Nogami K; Shima M; Nishiya K; Sakurai Y; Tanaka I; Giddings JC; Saenko EL; Yoshioka A
    Thromb Haemost; 2002 Mar; 87(3):459-65. PubMed ID: 11916079
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of antibodies to factor VIII in hemophilia A patients treated by immune tolerance therapy.
    Scandella D; Reyes H; Felch M; Sakurai Y
    Haematologica; 2000 Oct; 85(10 Suppl):86-8. PubMed ID: 11187882
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of a novel immunodominant cytotoxic T lymphocyte epitope derived from human factor VIII in a murine model of hemophilia A.
    Wang W; Merchlinsky M; Inman J; Golding B
    Thromb Res; 2005; 116(4):335-44. PubMed ID: 16038719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term persistence of anti-factor VIII antibody-secreting cells in hemophilic mice after treatment with human factor VIII.
    Hausl C; Maier E; Schwarz HP; Ahmad RU; Turecek PL; Dorner F; Reipert BM
    Thromb Haemost; 2002 May; 87(5):840-5. PubMed ID: 12038787
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors.
    Astermark J
    Haemophilia; 2006 Dec; 12 Suppl 6():8-13; discussion 13-4. PubMed ID: 17123388
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of anti-idiotypic antibodies with immune tolerance induction for the treatment of hemophilia A with inhibitors.
    Sakurai Y; Shima M; Tanaka I; Fukuda K; Yoshida K; Yoshioka A
    Haematologica; 2004 Jun; 89(6):696-703. PubMed ID: 15194537
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dominant C2 domain epitope specificity of inhibitor antibodies elicited by a heat pasteurized product, factor VIII CPS-P, in previously treated hemophilia A patients without inhibitors.
    Sawamoto Y; Prescott R; Zhong D; Saenko EL; Mauser-Bunschoten E; Peerlinck K; van den Berg M; Scandella D
    Thromb Haemost; 1998 Jan; 79(1):62-8. PubMed ID: 9459325
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
    Kubisz P; Plamenová I; Hollý P; Stasko J
    Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reactivity profile of anti-factor VIII antibodies with designed synthetic peptides mimicking epitopes of the C2 and a1 domains.
    Chaves DG; Velloso-Rodrigues C; Moreau V; Nguyen C; Villard S; Belisário AR; Granier C; Santoro MM
    Br J Haematol; 2008 May; 141(5):708-15. PubMed ID: 18422780
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epitope mapping of inhibitory antibodies targeting the C2 domain of coagulation factor VIII by hydrogen-deuterium exchange mass spectrometry.
    Sevy AM; Healey JF; Deng W; Spiegel PC; Meeks SL; Li R
    J Thromb Haemost; 2013 Dec; 11(12):2128-36. PubMed ID: 24152306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Immunoblotting analysis of acquired factor VIII inhibitor in an elderly man].
    Kikuchi M; Sano M; Shimamoto Y; Yamaguchi M; Tadano J; Takahashi I; Kamiya T
    Rinsho Ketsueki; 1993 Jul; 34(7):876-8. PubMed ID: 7689663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.